The drug, when given in addition to standard treatment, extended
median overall survival in 50 percent of newly-diagnosed
glioblastoma multiforme (GBM) patients to two years in a mid-stage
Usually GBM patients succumb to the disease in one year.
(Reporting by Natalie Grover in Bangalore; Editing by Joyjeet Das)
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.